Data-driven excellence: the cornerstone of clinical research
Essential areas such as study planning, interpretation, regulatory guidance, and key study design decisions remain human responsibilities, although AI increasingly supports routine tasks. X-act gets involved after the preclinical phase supporting clients in all clinical research phases from Phase I to IV and beyond. Their service ranges from initial planning to final analysis, reporting, and regulatory submission. European Biotechnology spoke with Jasmin Atarodi, Managing Director of X-act Cologne Clinical Research GmbH, about the benefits of partnering with experienced data specialists.
EuroBiotech_ As a specialised CRO, what are your core areas of expertise, and how do these services benefit your clients throughout the clinical study process?
Atarodi_ Our main strengths are in four areas – clinical data management, biostatistics, statistical programming and medical writing:
In clinical data management, we ensure data is captured accurately and in full compliance with all rules. Our workflows keep data quality and integrity high throughout.
Our biostatisticians design smart studies and select endpoints to effectively answer each scientific question. Our statistical programmers create efficient, tailored analysis packages ready for submission. Our medical writing team delivers all documentation clearly and professionally, meeting regulatory requirements. Close teamwork across these fields gives clients seamless support from a trusted partner throughout their study.
EuroBiotech_What advantages do specialised CROs have over full-service providers?
Atarodi_Specialised CROs provide genuine expertise in their chosen areas. Clients benefit from personal contact and quick decisions. Our experience in data management and biostatistics means we offer efficient, high-quality, and customised solutions, whether it’s data strategies, innovative statistics, or clear medical writing. Clients consistently tell us this specialisation makes their projects more efficient and cost-effective, while reducing error risks and providing greater planning security.
EuroBiotech_How do you ensure clients are well informed and personally supported in every project phase?
Atarodi_Strong project leadership starts with clear responsibility. Each client has a dedicated project leader at X-act, who acts as their main point of contact and link to all our specialists.
We keep clients updated with regular meetings and open communication on project status, milestones, issues, and next steps. Our flat structure and digital tools help us stay agile and responsive to changing client needs, ensuring involvement at every step.
EuroBiotech_From past collaborations with biotech and biopharma companies, what are the most important factors for success?
Atarodi_Success depends on real partnership, working together as equals. Our proactive approach makes a difference: we spot potential issues early and offer solutions before problems arise. Honest communication, efficient collaboration between all disciplines, and a clear focus on shared goals are essential. Our expertise lets us quickly understand individual client needs and provide targeted support. Clients often describe us as a responsible, forward-thinking partner who brings real value to their development.
Contact
business@x-act-cologne.com
This interview with Jasmin Atarodi, co-founder and managing director of X-act Cologne Clinical Research GmbH, was originally published in European Biotechnology Magazine Autumn 2025.
Julius Clinical
Menarini Group